The DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Adenosine receptors as therapeutic targets
Open accessAbstract
Adenosine receptors are major targets of caffeine, the most commonly consumed drug in the world. There is growing evidence that they could also be promising therapeutic targets in a wide range of conditions, including cerebral and cardiac ischaemic diseases, sleep disorders, immune and inflammatory disorders and cancer. After more than three decades of medicinal chemistry research, a considerable number of selective agonists and antagonists of adenosine receptors have been discovered, and some have been clinically evaluated, although none has yet received regulatory approval. However, recent advances in the understanding of the roles of the various adenosine receptor subtypes, and in the development of selective and potent ligands, as discussed in this review, have brought the goal of therapeutic application of adenosine receptor modulators considerably closer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among these, A1 and A2A receptors are considered the principal targets mediating caffeine’s physiological effects.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“A key mechanism underlying the interaction between caffeine and exercise is caffeine’s pharmacological action as a competitive adenosine receptor antagonist.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“Instead, competitive blockade of A1 and A2A adenosine receptors is widely regarded as the central mechanism underlying caffeine’s physiological effects during both habitual intake and exercise (Figure 1) [28,29,30,31].”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“Within the range of plasma concentrations relevant to sports nutrition practice, typically micromolar levels achieved after low-to-moderate caffeine intake, caffeine’s primary mechanism of action is unlikely to involve phosphodiesterase (PDE) inhibition or direct intracellular Ca2+ release.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“This effect modulates key physiological processes such as anti-inflammatory responses, angiogenesis, and vasodilation, as illustrated in Figure 2 (left panel) [52,66,67,68].”
From Comparison of Polynucleotide and Polydeoxyribonucleotide in Dermatology: Molecular Mechanisms and Clinical Perspectives (2025) · cites this paper as [68]
Citations
Cites
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Klotz, K.-N., & Linden, J. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01511-4 · Cited by 2,585
Self-citationCalker, D. V., Müller, M., & Hamprecht, B. (1979) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1979.tb05236.x · Cited by 1,371
Ohta, A., & Sitkovsky, M. (2001) · Nature · doi:10.1038/414916a · Cited by 1,334
Astrocytic Purinergic Signaling Coordinates Synaptic Networks
Pascual, O., Casper, K. B., Kubera, C., Zhang, J., Revilla-Sanchez, R., Sul, J.-Y., Takano, H., Moss, S. J., McCarthy, K., & Haydon, P. G. (2005) · Science · doi:10.1126/science.1116916 · Cited by 1,280
Adenosine: A Mediator of the Sleep-Inducing Effects of Prolonged Wakefulness
Porkka-Heiskanen, T., Strecker, R. E., Thakkar, M., Bjørkum, A. A., Greene, R. W., & McCarley, R. W. (1997) · Science · doi:10.1126/science.276.5316.1265 · Cited by 1,252
Subclasses of external adenosine receptors.
Londos, C., Cooper, D. M., & Wolff, J. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.5.2551 · Cited by 1,081
Extracellular metabolism of ATP and other nucleotides
Zimmermann, H. (2000) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s002100000309 · Cited by 990
Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor
Ledent, C., Vaugeois, J.-M., Schiffmann, S. N., Pedrazzini, T., Yacoubi, M. E., Vanderhaeghen, J.-J., Costentin, J., Heath, J. K., Vassart, G., & Parmentier, M. (1997) · Nature · doi:10.1038/41771 · Cited by 918
Adenosine: an endogenous regulator of innate immunity
Haskó, G. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.11.003 · Cited by 899
Research works printed but not linked: 1
- Ji, X. D. & Jacobson, K. A. [3H]-ZM241385 as a radioligand at recombinant human A2B adenosine receptors. Drug Des. Discov. 16, 217–226 (1999).
Cited by
Receptors for Purines and Pyrimidines
Burnstock, G., & Verkhratsky, A. (2012) · Purinergic Signalling and the Nervous System · doi:10.1007/978-3-642-28863-0_5 · Cited by 3,958
The 2.6 Angstrom Crystal Structure of a Human A 2A Adenosine Receptor Bound to an Antagonist
Jaakola, V.-P., Griffith, M. T., Hanson, M. A., Cherezov, V., Chien, E. Y. T., Lane, J. R., IJzerman, A. P., & Stevens, R. C. (2008) · Science · doi:10.1126/science.1164772 · Cited by 1,781
Physiology and Pathophysiology of Purinergic Neurotransmission
Burnstock, G. (2007) · Physiological Reviews · doi:10.1152/physrev.00043.2006 · Cited by 1,585
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Linden, J., & Müller, C. E. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003285 · Cited by 1,301
“Selective agonists and antagonists for all four adenosine receptor subtypes are available (Müller, 2000a,b; Yan et al., 2003; Jacobson and Gao, 2006; Müller and Ferré, 2007; Elzein and Zablocki, 2008; Müller and Jacobson, 2011).”
BackgroundSelf-citationAdenosine receptors: therapeutic aspects for inflammatory and immune diseases
Haskó, G., Linden, J., Cronstein, B., & Pacher, P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2638 · Cited by 1,217
“However, it is now known to be also linked to various kinase pathways including protein kinase C (PKC), phosphoinositide 3 (PI3) kinase and mitogen-activated protein (MAP) kinase”
BackgroundYegutkin, G. G. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.01.024 · Cited by 1,154
Adenosine receptors as drug targets — what are the challenges?
Chen, J.-F., Eltzschig, H. K., & Fredholm, B. B. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3955 · Cited by 895
Purinergic signalling in neuron–glia interactions
Fields, R. D., & Burnstock, G. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1928 · Cited by 857
Immune cell regulation by autocrine purinergic signalling
Junger, W. G. (2011) · Nature Reviews Immunology · doi:10.1038/nri2938 · Cited by 810
“Compared to the P2 receptors, a much wider selection of powerful and specific drugs is available for the modulation of adenosine receptor”
BackgroundChromone: A Valid Scaffold in Medicinal Chemistry
Gaspar, A., Matos, M. J., Garrido, J., Uriarte, E., & Borges, F. (2014) · Chemical Reviews · doi:10.1021/cr400265z · Cited by 760
Intestinal Bacteria and the Regulation of Immune Cell Homeostasis
Hill, D. A., & Artis, D. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101330 · Cited by 586
Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function
Shifrut, E., Carnevale, J., Tobin, V., Roth, T. L., Woo, J. M., Bui, C. T., Li, P. J., Diolaiti, M. E., Ashworth, A., & Marson, A. (2018) · Cell · doi:10.1016/j.cell.2018.10.024 · Cited by 573
Structure of the Adenosine A2A Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine
Doré, A. S., Robertson, N., Errey, J. C., Ng, I., Hollenstein, K., Tehan, B., Hurrell, E., Bennett, K., Congreve, M., Magnani, F., et al. (2011) · Structure · doi:10.1016/j.str.2011.06.014 · Cited by 553
“The receptors are widely expressed in the brain, cardiovascular and immune system and there is growing evidence that drugs acting at adenosine receptors represent promising approaches in a wide range of diseases (Jacobson and Gao, 2006).”
BackgroundThe Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
Toh, W. S., Lai, R. C., Hui, J. H. P., & Lim, S. K. (2017) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.11.008 · Cited by 502
Progress and perspectives on targeting nanoparticles for brain drug delivery
Gao, H. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.05.013 · Cited by 495
Recent developments in adenosine receptor ligands and their potential as novel drugs
Müller, C. E., & Jacobson, K. A. (2011) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2010.12.017 · Cited by 431
“A1 receptor antagonists—Various A1AR antagonists, xanthines and nonxanthines, have been or are currently being explored for clinical applications [109] for heart failure, and for improving renal function and treatment of acute renal failure.”
BackgroundSelf-citationOpportunities for Tapping into Three-Dimensional Chemical Space through a Quaternary Carbon
Talele, T. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00829 · Cited by 424
Adenosine Receptors: Expression, Function and Regulation
Sheth, S., Brito, R., Mukherjea, D., Rybak, L., & Ramkumar, V. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15022024 · Cited by 401
“In turn, the A3AR can regulate the activity of PLC via a pertussis toxin-sensitive G protein in rat basophilic leukemia cells [19,20] or by direct coupling to Gq protein [5,21].”
BackgroundDrugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Atkin, T., Comai, S., & Gobbi, G. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014381 · Cited by 391
“Other receptors involved in sleep, but which remain to be pharmacologically exploited, include the adenosine A1 and A2 receptors (Jacobson and Gao, 2006).”
BackgroundFluorescence polarization assays in small molecule screening
Lea, W. A., & Simeonov, A. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.537322 · Cited by 379
“A2AAR is one of the four known subtypes of adenosine receptors (ARs), all of which are members of the GPCR superfamily [29].”
BackgroundAdenosine promotes alternative macrophage activation via A2A and A2B receptors
Csóka, B., Selmeczy, Z., Koscsó, B., Németh, Z. H., Pacher, P., Murray, P. J., Kepka‐Lenhart, D., Jr., S. M. M., Gause, W. C., Leibovich, S. J., et al. (2012) · The FASEB Journal · doi:10.1096/fj.11-190934 · Cited by 376
“4 transmembrane adenosine receptors, designated A1, A2A, A2B, and A3 (22).”
BackgroundChallenges and Opportunities for the Application of Boron Clusters in Drug Design
Leśnikowski, Z. J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01932 · Cited by 348
Structure of the adenosine-bound human adenosine A1 receptor–Gi complex
Draper-Joyce, C. J., Khoshouei, M., Thal, D. M., Liang, Y.-L., Nguyen, A. T. N., Furness, S. G. B., Venugopal, H., Baltos, J.-A., Plitzko, J. M., Danev, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0236-6 · Cited by 317
Adenosine Kinase: Exploitation for Therapeutic Gain
Boison, D. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.006361 · Cited by 310
“The pharmacology and physiologic functions of the adenosine receptors have extensively been reviewed (Fredholm et al., 2000, 2001a, 2011a,b; Jacobson and Gao, 2006; Sebastiao and Ribeiro, 2009a; Stone et al., 2009) and only key functions will briefly be outlined below.”
BackgroundInfluentialYegutkin, G. G. (2014) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2014.953627 · Cited by 299
Sleep homeostasis: a role for adenosine in humans?
Landolt, H.-P. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.02.024 · Cited by 290
“This adenosine receptor subtype inhibits adenylate cyclase, stimulates PLC and calcium mobilization, and activates ERK1/2 phosphorylation [3,6].”
BackgroundInfluentialMechanisms of sensorineural cell damage, death and survival in the cochlea
Wong, A. C. Y., & Ryan, A. F. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00058 · Cited by 282
“Adenosine is released from tissue in response to stress as a cytoprotectant, augments antioxidant defense, increases oxygen supply, improves blood flow, inhibits the release of neurotransmitters, stabilizes cells by stimulating K channels and inhibiting Ca2+ channels, triggers antiinflammatory responses, and promotes…”
BackgroundStructure of the Adenosine A1 Receptor Reveals the Basis for Subtype Selectivity
Glukhova, A., Thal, D. M., Nguyen, A. T., Vecchio, E. A., Jörg, M., Scammells, P. J., May, L. T., Sexton, P. M., & Christopoulos, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.042 · Cited by 275
Adenosine A 2A Receptor as a Drug Discovery Target
de Lera Ruiz, M., Lim, Y.-H., & Zheng, J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4011669 · Cited by 276
Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008
participants, G. D. 2., Michino, M., Abola, E., Brooks, C. L., Dixon, J. S., Moult, J., & Stevens, R. C. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2877 · Cited by 276
“Adenosine receptors belong to the class A rhodopsin-like GPCR family and represent promising therapeutic targets in a wide range of conditions, including cerebral and cardiac ischaemic diseases, sleep disorders, immune and inflammatory disorders, and cance”
BackgroundVennekens, R., Olausson, J., Meissner, M., Bloch, W., Mathar, I., Philipp, S. E., Schmitz, F., Weissgerber, P., Nilius, B., Flockerzi, V., et al. (2007) · Nature Immunology · doi:10.1038/ni1441 · Cited by 268
“In contrast, adenosine stimulation involves the activation of G αi protein–coupled A 3 adenosine receptors in mouse mast cells, which leads to the activation of phospholipase C and phospholipase D through G βγ protein and phosphatidylinositol-3-OH kinase-&gamma”
BackgroundRegulators of endothelial and epithelial barrier integrity and function in acute lung injury
Lucas, R., Verin, A. D., Black, S. M., & Catravas, J. D. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.01.014 · Cited by 263
“Purinoreceptors are divided into two classes: P1 or adenosine receptors and P2, which recognize primarily extracellular ATP, ADP, UTP and UDP [31,32].”
BackgroundCaffeine analogs: biomedical impact
Daly, J. W. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7051-9 · Cited by 256
Chemical sensing of neurotransmitters
Pradhan, T., Jung, H. S., Jang, J. H., Kim, T. W., Kang, C., & Kim, J. S. (2014) · Chem. Soc. Rev. · doi:10.1039/c3cs60477b · Cited by 256
Zavialov, A. V., Gracia, E., Glaichenhaus, N., Franco, R., Zavialov, A. V., & Lauvau, G. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.1109764 · Cited by 250
“that inhibits adenylyl cyclase (Gi), whereas the activation of A2A and A2B receptors causes the opposite effect by triggering a G protein that activates adenylyl cyclase (Gs) [2].”
BackgroundStructure-Based Discovery of Novel Chemotypes for Adenosine A2AReceptor Antagonists
Katritch, V., Jaakola, V.-P., Lane, J. R., Lin, J., IJzerman, A. P., Yeager, M., Kufareva, I., Stevens, R. C., & Abagyan, R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901647p · Cited by 245
REM Sleep Instability – A New Pathway for Insomnia?
Riemann, D., Spiegelhalder, K., Nissen, C., Hirscher, V., Baglioni, C., & Feige, B. (2012) · Pharmacopsychiatry · doi:10.1055/s-0031-1299721 · Cited by 242
Adenosine kinase, epilepsy and stroke: mechanisms and therapies
Boison, D. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.10.008 · Cited by 241
A2A receptors in inflammation and injury: lessons learned from transgenic animals
Haskó, G., & Pacher, P. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0607359 · Cited by 240
“Selective antagonists for the A2A receptor are also available, and they include ZM241385 (4-{2-[7amino-2-(2-furyl) (1, 2, 4)triazolo(2,3-a) (1, 3, 5)triazin-5-ylamino]ethyl}-phenol) and SCH 58621 {5-amino-7-(2phenylethyl)-2-(2-furyl)-pyrazolo[4,3-(ε)]-1,2,4-triazolo(1,5-c)pyrimidine [26]}.”
MethodChen, J.-F., Sonsalla, P. K., Pedata, F., Melani, A., Domenici, M. R., Popoli, P., Geiger, J., Lopes, L. V., & de Mendonça, A. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.09.002 · Cited by 239
Christopoulos, A., Changeux, J.-P., Catterall, W. A., Fabbro, D., Burris, T. P., Cidlowski, J. A., Olsen, R. W., Peters, J. A., Neubig, R. R., Pin, J.-P., et al. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.008862 · Cited by 238
“The isomerization of a receptor macromolecule between different conformational states.”
BackgroundA2B adenosine receptors in immunity and inflammation
Haskó, G., Csóka, B., Németh, Z. H., Vizi, E. S., & Pacher, P. (2009) · Trends in Immunology · doi:10.1016/j.it.2009.04.001 · Cited by 232
“Adenosine is a primordial regulator of multiple physiological processes and its modulatory actions have been demonstrated in organisms as diverse as Drosophila [1], the common mussel Mytilus edulis [2], the protozoan Leishmania mexicana [3] and mammals such as Mus musculus [ 4 ,5] and humans [4,5].”
BackgroundStructure-Based Discovery of A 2A Adenosine Receptor Ligands
Carlsson, J., Yoo, L., Gao, Z.-G., Irwin, J. J., Shoichet, B. K., & Jacobson, K. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100240h · Cited by 227
Self-citationThe adenosine kinase hypothesis of epileptogenesis
Boison, D. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.12.002 · Cited by 225
The A3 adenosine receptor: An enigmatic player in cell biology
Gessi, S., Merighi, S., Varani, K., Leung, E., Mac Lennan, S., & Borea, P. A. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.002 · Cited by 224
Release of Adenosine and ATP During Ischemia and Epilepsy
Dale, N., & Frenguelli, B. (2009) · Current Neuropharmacology · doi:10.2174/157015909789152146 · Cited by 224
“Realising many of these challenges is within sight: purine research has had a welcome shot in the arm through the role of purines in gliotransmission, connexins/pannexins as purine channels, and the realisation that the widespread (side) effects of purines described by Drury & Szent-Györgyi can be circumvented, creati…”
BackgroundAdenosine as a neuromodulator in neurological diseases
BOISON, D. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.09.002 · Cited by 221
“The purine ribonucleoside adenosine controls many brain functions in physiological and pathophysiological conditions via activation of high-affinity A1 or A2A, low-affinity A2B, or low-abundance A3 adenosine receptors (ARs) [1,2].”
BackgroundInfluentialCheng, R. K. Y., Segala, E., Robertson, N., Deflorian, F., Doré, A. S., Errey, J. C., Fiez-Vandal, C., Marshall, F. H., & Cooke, R. M. (2017) · Structure · doi:10.1016/j.str.2017.06.012 · Cited by 217
The Role of Adenosine in the Regulation of Sleep
Huang, Z.-L., Urade, Y., & Hayaishi, O. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611795347654 · Cited by 218
“On the other hand, activation of the A2AR subtype increases adenylate cyclase activity through activation of Gs or Golf (in the striatum) proteins, induces the formation of inositol phosphates, and activates protein kinase C [33, 56].”
BackgroundEquilibrative nucleoside transporters—A review
Boswell-Casteel, R. C., & Hays, F. A. (2017) · Nucleosides, Nucleotides and Nucleic Acids · doi:10.1080/15257770.2016.1210805 · Cited by 209
Thiazole: A promising heterocycle for the development of potent CNS active agents
Mishra, C. B., Kumari, S., & Tiwari, M. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.12.031 · Cited by 209
Specificity of the ecto‐ATPase inhibitor ARL 67156 on human and mouse ectonucleotidases
Lévesque, S. A., Lavoie, É. G., Lecka, J., Bigonnesse, F., & Sévigny, J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707361 · Cited by 209
“One nucleoside in particular, adenosine, can, in turn, act as a signalling molecule via the activation of four ubiquitous receptors (A1, A2a, A2b and A3) (Jacobson and Gao, 2006).”
BackgroundAdenosine receptors as drug targets
Fredholm, B. B. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.02.004 · Cited by 207
“These have been complemented by non-xanthine antagonists and several receptor-selective agonists, and we now are in the fortunate position to have a set of apparently quite selective pharmacological tools [1], [20-23].”
BackgroundHistorical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development
Jacobson, K. A., Tosh, D. K., Jain, S., & Gao, Z.-G. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00124 · Cited by 198
“Imaging Many adenosine derivatives that proved to be A2AAR-selective agonists have bulky, hydrophobic substitution at the C2 position of adenine (Jacobson and Gao, 2006).”
BackgroundInfluentialSelf-citationThe Impact of Coffee on Health
Nieber, K. (2017) · Planta Medica · doi:10.1055/s-0043-115007 · Cited by 195
“Pharmacological studies have confirmed that A1 receptor activation has a number of effects in the cardiovascular system, including a reduction in heart rate and atrial contractility, and the attenuation of the stimulatory actions of catecholamines on the heart, and the A2A receptors are involved in vasodilation in the…”
BackgroundAgis-Torres, A., Sollhuber, M., Fernandez, M., & Sanchez-Montero, J. M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660047 · Cited by 202
Adenosine dysfunction in epilepsy
Boison, D. (2012) · Glia · doi:10.1002/glia.22285 · Cited by 200
Adenosine receptor targets for pain
Sawynok, J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.10.031 · Cited by 199
“It can regulate diverse functions such as cardiovascular, respiratory and renal function, inflammatory and immune events, and CNS events, and there has been considerable interest in developing adenosine-based therapeutics for conditions involving these systems (Jacobson and Gao, 2006; Schenone et al., 2010; Gessi et a…”
BackgroundCoupling of P2Y receptors to G proteins and other signaling pathways
Erb, L., & Weisman, G. A. (2012) · Wiley Interdisciplinary Reviews: Membrane Transport and Signaling · doi:10.1002/wmts.62 · Cited by 196
Descalzi, G., Mitsi, V., Purushothaman, I., Gaspari, S., Avrampou, K., Loh, Y.-H. E., Shen, L., & Zachariou, V. (2017) · Science Signaling · doi:10.1126/scisignal.aaj1549 · Cited by 188
Burnstock, G. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788186335 · Cited by 195
“Specific agonists and antagonists are available for the P1 receptor subtypes [54].”
BackgroundAdenosine hypothesis of schizophrenia – Opportunities for pharmacotherapy
Boison, D., Singer, P., Shen, H.-Y., Feldon, J., & Yee, B. K. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.048 · Cited by 191
“Central effects of adenosinearemediated via activationof the two high-affinity adenosine receptors A1R and A2AR and the two lowaffinity and low-abundance receptors A2B and A3 (Boison, 2007a,b; Fredholm et al., 2005; Jacobson and Gao, 2006) which are coupled to inhibitory (A1R, A3R) or stimulatory (A2AR, A2BR) metabotr…”
BackgroundProstatic Acid Phosphatase Is an Ectonucleotidase and Suppresses Pain by Generating Adenosine
Zylka, M. J., Sowa, N. A., Taylor-Blake, B., Twomey, M. A., Herrala, A., Voikar, V., & Vihko, P. (2008) · Neuron · doi:10.1016/j.neuron.2008.08.024 · Cited by 187
“In support of this, there are four adenosine receptor subtypes, with A1 and A3 coupled to inhibitory Gi-proteins and A2a and A2b coupled to stimulatory Gq- and Gs-proteins (Jacobson and Gao, 2006).”
Adenosine signalling in diabetes mellitus—pathophysiology and therapeutic considerations
Antonioli, L., Blandizzi, C., Csóka, B., Pacher, P., & Haskó, G. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.10 · Cited by 183
Adenosine, caffeine, and sleep–wake regulation: state of the science and perspectives
Reichert, C. F., Deboer, T., & Landolt, H. (2022) · Journal of Sleep Research · doi:10.1111/jsr.13597 · Cited by 183
“…receptors have long been recognised as possible therapeutic targets for the pharmacological treatment of sleep disturbances (Chen et al., 2013; Jacobson & Gao, 2006), no approved drugs to ameliorate disturbed wakefulness and sleep by specifically targeting the adenosine neuromodulatory system…”
BackgroundGuo, D., Mulder‐Krieger, T., IJzerman, A. P., & Heitman, L. H. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01897.x · Cited by 179
“In this study, we focused on agonists for the human adenosine A2A receptor (hA2A receptor), which have clinical relevance in various pathological conditions such as respiratory disorders and inflammatory conditions (Jacobson and Gao, 2006).”
MethodAdenosine receptor antagonists for cognitive dysfunction: a review of animal studies
Takahashi, R. N. (2008) · Frontiers in Bioscience · doi:10.2741/2870 · Cited by 174
“Caffeine also directly increases dopamine release from striatal nerve terminals (142), an effect which is also mimicked by the selective adenosine A2A receptor antagonist ZM241385 in striatal synaptosomes (143).”
BackgroundInfluentialPurinergic Mechanisms and Pain
Burnstock, G. (2016) · Advances in Pharmacology · doi:10.1016/bs.apha.2015.09.001 · Cited by 176
Pain-relieving prospects for adenosine receptors and ectonucleotidases
Zylka, M. J. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.12.006 · Cited by 172
“These side effects might result from the activation of adenosine A2 receptors—receptors that have pronociceptive (—pain-producing ) and vasodilatory effects when activated peripherally [1,11].”
Adenosine Receptors and Inflammation
Blackburn, M. R., Vance, C. O., Morschl, E., & Wilson, C. N. (2009) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-89615-9_8 · Cited by 171
Cardiotoxicity Associated with Targeting Kinase Pathways in Cancer
Mellor, H. R., Bell, A. R., Valentin, J.-P., & Roberts, R. R. A. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfq378 · Cited by 168
“…cytoprotective role in the body, mediated via four broad categories of activity: increasing the ratio of oxygen supply to demand, protecting against ischemic damage by cell conditioning , triggering anti-inflammatory responses, and the promotion of angiogenesis (Jacobson and Gao, 2006 ).”
BackgroundCD73 and adenosine generation in the creation of regulatory microenvironments
Regateiro, F. S., Cobbold, S. P., & Waldmann, H. (2012) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2012.04623.x · Cited by 166
Generation of anti‐inflammatory adenosine byleukocytes is regulated by TGF‐β
Regateiro, F. S., Howie, D., Nolan, K. F., Agorogiannis, E. I., Greaves, D. R., Cobbold, S. P., & Waldmann, H. (2011) · European Journal of Immunology · doi:10.1002/eji.201141512 · Cited by 166
Gao, X., Qian, J., Zheng, S., Changyi, Y., Zhang, J., Ju, S., Zhu, J., & Li, C. (2014) · ACS Nano · doi:10.1021/nn5003375 · Cited by 162
Storey, R. F., James, S. K., Siegbahn, A., Varenhorst, C., Held, C., Ycas, J., Husted, S. E., Cannon, C. P., Becker, R. C., Steg, P. G., et al. (2014) · Platelets · doi:10.3109/09537104.2013.842965 · Cited by 162
“Some studies have shown potential for adenosine to reduce pulmonary injury [7].”
BackgroundContribution of Adenosine A2B Receptors to Inflammatory Parameters of Experimental Colitis
Frick, J.-S., MacManus, C. F., Scully, M. M., Glover, L. E., Eltzschig, H. K., & Colgan, S. P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801324 · Cited by 157
Mechanotransduction and cell biomechanics of the intervertebral disc
Fearing, B. V., Hernández, P., Setton, L. A., & Chahine, N. O. (2018) · JOR Spine · doi:10.1002/jsp2.1026 · Cited by 168
2-Amino-6-furan-2-yl-4-substituted Nicotinonitriles as A2A Adenosine Receptor Antagonists
Mantri, M., de Graaf, O., van Veldhoven, J., Göblyös, A., Künzel, J. K. V. F. D., Mulder‐Krieger, T., Link, R., de Vries, H., Beukers, M. W., Brussee, J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701594y · Cited by 149
Hodgson, R. A., Bertorelli, R., Varty, G. B., Lachowicz, J. E., Forlani, A., Fredduzzi, S., Cohen-Williams, M. E., Higgins, G. A., Impagnatiello, F., Nicolussi, E., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.149617 · Cited by 149
“There are four G-protein-coupled adenosine receptors (A1, A2A, A2B, and A3), so classified based on pharmacology and signal transduction mechanisms (Jacobson and Gao, 2006).”
BackgroundRoles of Adenosine and Its Receptors in Sleep–Wake Regulation
Huang, Z., Zhang, Z., & Qu, W. (2014) · International review of neurobiology · doi:10.1016/b978-0-12-801022-8.00014-3 · Cited by 167
Mi, T., Abbasi, S., Zhang, H., Uray, K., Chunn, J. L., Xia, L., Molina, J. G., Weisbrodt, N. W., Kellems, R. E., Blackburn, M. R., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33467 · Cited by 143
Impact of Ectoenzymes on P2 and P1 Receptor Signaling
Kukulski, F., Lévesque, S. A., & Sévigny, J. (2011) · Advances in pharmacology · doi:10.1016/b978-0-12-385526-8.00009-6 · Cited by 144
The birth and postnatal development of purinergic signalling
Burnstock, G., Fredholm, B. B., North, R. A., & Verkhratsky, A. (2010) · Acta Physiologica · doi:10.1111/j.1748-1716.2010.02114.x · Cited by 158
“For further reading on adenosine receptors, we recommend to the curious reader a number of excellent reviews (Olah & Stiles 2000, Fredholm et al. 2005, 2007, Jacobson & Gao 2006, Dare et al. 2007, Klaasse et al. 2008, Jenner et al. 2009).”
MethodKatritch, V., Rueda, M., Lam, P. C., Yeager, M. J., & Abagyan, R. A. (2009) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.22507 · Cited by 141
Guanosine and its role in neuropathologies
Bettio, L. E. B., Gil‐Mohapel, J., & Rodrigues, A. L. S. (2016) · Purinergic Signalling · doi:10.1007/s11302-016-9509-4 · Cited by 157
Adenosine receptor signaling: a key to opening the blood–brain door
Bynoe, M. S., Viret, C., Yan, A., & Kim, D.-G. (2015) · Fluids and Barriers of the CNS · doi:10.1186/s12987-015-0017-7 · Cited by 148
“The expression level of ARs varies depending on the type of cells or organs where they are expressed [22].”
BackgroundAdenosine—a physiological or pathophysiological agent?
Fredholm, B. B. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1101-6 · Cited by 140
Molecular Determinants of CGS21680 Binding to the Human Adenosine A2A Receptor
Lebon, G., Edwards, P. C., Leslie, A. G. W., & Tate, C. G. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.097360 · Cited by 133
“1), some of which display high potency and selectivity toward one receptor subtype (Jacobson and Gao, 2006).”
BackgroundInfluentialLiang, Y.-L., Zhao, P., Draper-Joyce, C. J., Baltos, J., Glukhova, A., Truong, T. T., May, L. T., Christopoulos, A., Wootten, D. L., Sexton, P. M., et al. (2018) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.8b00017 · Cited by 126
Xanthines as Adenosine Receptor Antagonists
Müller, C. E., & Jacobson, K. A. (2010) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-13443-2_6 · Cited by 146
Self-citationAdenosine signaling during acute and chronic disease states
Karmouty‐Quintana, H., Xia, Y., & Blackburn, M. R. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-0997-1 · Cited by 144
“Please see the following reviews for more information on the functions of these receptors in acute and chronic disease processes [25, 42, 43].”
BackgroundInfluentialXanthine scaffold: scope and potential in drug development
Singh, N., Shreshtha, A. K., Thakur, M. S., & Patra, S. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e00829 · Cited by 131
“Caffeine and theophylline are the earliest compounds indentified with antagonist activity for adenosine receptors but with moderate selectivity [32, 136, 137].”
BackgroundOuyang, X., Ghani, A., Malik, A. F., Wilder, T., Colegio, O. R., Flavell, R. A., Cronstein, B. N., & Mehal, W. Z. (2013) · Nature Communications · doi:10.1038/ncomms3909 · Cited by 144
Prevention of hyperoxia-mediated pulmonary inflammation in neonatal rats by caffeine
Weichelt, U., Cay, R., Schmitz, T., Strauss, E., Sifringer, M., Bührer, C., & Endesfelder, S. (2012) · European Respiratory Journal · doi:10.1183/09031936.00012412 · Cited by 139
Durst, R. Y., Danenberg, H. D., Gallily, R., Mechoulam, R., Meir, K., Grad, E., Beeri, R., Pugatsch, T., Tarsish, E., & Lotan, C. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00098.2007 · Cited by 134
“A1 receptor overexpression increases myocardial resistance to ischemia (12).”
Mediero, A., & Cronstein, B. N. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.02.001 · Cited by 133
“A variety of selective adenosine receptor agonists and antagonists have been identified, based on structural similarities to agonists such as adenosine, or antagonists such as xanthines or caffeine and theophylline [4] (Table 1).”
BackgroundInfluentialAMP Is an Adenosine A1 Receptor Agonist
Rittiner, J. E., Korboukh, I., Hull-Ryde, E. A., Jin, J. J., Janzen, W. P., Frye, S. V., & Zylka, M. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.291666 · Cited by 127
Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells
Kaljas, Y., Liu, C., Skaldin, M., Wu, C., Zhou, Q., Lu, Y., Aksentijevich, I. A., & Zavialov, A. V. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2357-0 · Cited by 131
“As a result, an array of adenosine receptor agonists and antagonists has been designed for use as potential drugs to tackle a variety of health problems [1, 5, 6].”
BackgroundThe Role of Altered BDNF/TrkB Signaling in Amyotrophic Lateral Sclerosis
Pradhan, J., Noakes, P. G., & Bellingham, M. C. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00368 · Cited by 146
“Extracellularly, it is produced by ectonucleotidase degradation of ATP released by neurons and astrocytes, and intracellularly by production during breakdown of ATP during high energy demand, followed by transport into the extracellular space (Jacobson and Gao, 2006).”
Background
Metadata
- Authors
- Jacobson, K. A., & Gao, Z.-G.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Jacobson, Kenneth A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-03
- Volume
- 5
- Issue
- 3
- Pages
- 247-264
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC3463109
- OpenAlex
- W1985598247
- Cited by
- 1,431
- References
- 215
- Citations by year
- 2026: 34 · 2025: 50 · 2024: 52 · 2023: 55 · 2022: 80 · 2021: 58 · 2020: 65 · 2019: 79 · 2018: 66 · 2017: 59 · 2016: 65 · 2015: 64 · 2014: 80 · 2013: 80 · 2012: 83
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (Z01DK031117)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- adenosine receptors, adenosine receptor agonists, adenosine receptor antagonists, selective ligands, caffeine, cardiovascular disease, ischemic diseases, sleep disorders, inflammatory diseases, cancer, neurological disorders, drug development
- MeSH terms
- Animals, Disease, Drug Therapy, Humans, Ligands, Structure-Activity Relationship, Molecular Structure, Signal Transduction, Receptors, Purinergic P1, Purinergic P1 Receptor Agonists, Purinergic P1 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.